~62% · $380K/day
Will the FDA approve a new GLP-1 obesity drug (beyond Ozempic/Wegovy) in 2026?
Eli Lilly, Pfizer pipeline — high-volume FDA market
Healthcare Prediction Markets
FDA Drug Approval & Healthcare Prediction Markets — 2026
New GLP-1 drug approval at 62%, mRNA cancer vaccine breakthrough at 38%, RFK Jr. FDA process change at 42%. Healthcare prediction markets on Polymarket and Kalshi price every major FDA and policy milestone — compare cross-venue healthcare odds in one search.
Top FDA & Healthcare Prediction Markets 2026
~55% · $220K/day
Will Alzheimer's drug lecanemab (Leqembi) show slowing in Phase 4 trials by 2026?
Long-running disease modification market
~38% · $290K/day
Will a cancer vaccine (mRNA) receive FDA approval or breakthrough designation in 2026?
Moderna/Merck mRNA cancer vaccine pipeline
~42% · $340K/day
Will RFK Jr. make major changes to FDA drug approval processes by end of 2026?
Policy change market — HHS leadership
~48% · $160K/day
Will US life expectancy increase above pre-COVID levels by end of 2026?
Public health recovery market
What drives the 2026 FDA & health odds
The forces moving the drug-approval and policy markets — each reprices on trial data, PDUFA dates, or HHS signals.
Clinical trial readouts
Phase 3 data is the binary catalyst — strong results pull approval markets up ahead of the PDUFA date.
PDUFA decision dates
The FDA’s target action dates are scheduled flashpoints; approval/complete-response letters resolve the markets.
HHS / RFK Jr. policy
Leadership signals on process, vaccines, and pricing drive the FDA-reform and policy markets.
GLP-1 & commercial stakes
Multi-billion-dollar obesity-drug economics make the GLP-1 pipeline the highest-volume FDA market.
Related Hubs
Macro
Biotech 2026
Pharma M&A, pipeline & valuations — the company side of FDA outcomes
AI
AGI 2026
AI drug discovery — AI-accelerated FDA pipeline
Macro
Recession 2026
Healthcare spending & the macro backdrop
FAQ
Are there prediction markets for FDA drug approvals in 2026?
Yes. Polymarket and Kalshi both carry active FDA approval markets — GLP-1 drugs (obesity treatment pipeline), Alzheimer's disease-modifying therapies, mRNA cancer vaccines, and specific PDUFA date outcomes. The GLP-1 market is the highest-volume FDA prediction market with $380K in daily trading, reflecting the massive commercial stakes around Eli Lilly and Pfizer's pipeline.
What prediction markets exist for GLP-1 obesity drugs beyond Ozempic?
Polymarket has active markets for: FDA approval of Eli Lilly's orforglipron (oral GLP-1), FDA approval of Pfizer's danuglipron, and broader questions about new GLP-1 class approvals. With Ozempic/Wegovy already generating $15B+/year, the pipeline market is highly watched. Prediction markets price a new FDA-approved GLP-1 entrant at ~62% in 2026.
How do healthcare prediction markets work for investors?
FDA approval prediction markets function like binary event bets — they resolve YES/NO based on official FDA announcements. These markets often trade well before PDUFA (target action) dates and can price in insider-knowledge-level probability faster than sell-side analyst reports. Kalshi is particularly active for pharmaceutical regulatory milestones because of its regulatory compliance framework.
What effect will RFK Jr. have on FDA approval markets?
Robert F. Kennedy Jr. as HHS Secretary has created an active prediction market category: FDA process change markets. Prediction markets price major FDA approval process changes at ~42%, reflecting uncertainty about the scope of his influence on established agency procedures. These markets move with RFK Jr.'s public statements and any formal FDA rule proposals.
How do FDA approval markets connect to biotech stock and M&A markets?
An FDA approval (or rejection) is the single biggest value event for a drug developer, so the FDA markets and the biotech equity/M&A markets are tightly coupled: a positive readout can re-rate a stock or trigger an acquisition. Trading the Health/FDA hub alongside the Biotech 2026 hub captures both the regulatory event and its corporate consequences — Mantis cross-links them.
Why are PDUFA dates important for trading these markets?
A PDUFA date is the FDA’s target deadline to decide on a drug application, so it is a known, scheduled catalyst — prediction markets often build in a probability well ahead of it and then resolve sharply on the announcement. Knowing the PDUFA calendar lets traders anticipate when an FDA market will move, much like an earnings date for a stock. Mantis surfaces the relevant contracts for any drug query.